

ABSTRACT OF THE DISCLOSURE

5 The present invention discloses development of a model
live vaccine for HIV, using an attenuated strain of *Salmonella*
engineered to surface express specific HIV proteins and testing of
this vaccine in mice. There are provided two recombinant plasmids,
containing the Lpp-OmpA genes required for surface exposure,
10 followed by the genes for the HIV-1 proteins, Reverse Transcriptase
or Transactivating protein (Tat). These plasmids are electroporated
into an attenuated strain of *Salmonella*, and antigen expression is
verified. These live vaccines are then used to orally inoculate mice
and the vaccinated mice are tested for fecal IgA response and helper
15 T cell response specific for the HIV antigens.